Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
PDA Journal of Pharmaceutical Science and Technology|February 2, 2012
Application of quality by design in the control of adventitious viruses: gaps in current processes in the prevention of virus contaminantsBarry Cherney
Annals of the New York Academy of Sciences|January 16, 2010
Hurdles and leaps for protein therapeuticsSteven Kozlowski, Barry Cherney, Raymond P Donnelly
PDA Journal of Pharmaceutical Science and Technology|February 2, 2012
Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practicesAmy S Rosenberg, Barry Cherney, Kurt Brorson, et al.
Cancer Immunology, Immunotherapy : CII|August 23, 2002
Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatinLei Yao, Sandra E Pike, Stefania Pittaluga, et al.
PDA Journal of Pharmaceutical Science and Technology|October 3, 2015
Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology ProductsKim Li, Gary Rogers, Yasser Nashed-Samuel, et al.
Biologicals : Journal of the International Association of Biological Standardization|August 13, 2010
Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigationJohn Carpenter, Barry Cherney, Anthony Lubinecki, et al.
Nature Reviews. Drug Discovery|July 20, 2007
The FDA's assessment of follow-on protein products: a historical perspectiveJanet Woodcock, Joseph Griffin, Rachel Behrman, et al.
Pageof 1